VolitionRX (NYSEAMERICAN:VNRX) Shares Cross Below Fifty Day Moving Average – Here’s Why

VolitionRX Limited (NYSEAMERICAN:VNRX)’s stock price crossed below its 50-day moving average during trading on Wednesday . The stock has a 50-day moving average of $2.76 and traded as low as $1.32. VolitionRX shares last traded at $1.39, with a volume of 228,591 shares trading hands.

Analysts Set New Price Targets

VNRX has been the subject of several analyst reports. Citigroup cut VolitionRX to a “hold” rating in a report on Monday, April 20th. HC Wainwright dropped their target price on VolitionRX from $30.00 to $20.00 and set a “buy” rating for the company in a report on Thursday, April 2nd. Benchmark restated a “hold” rating on shares of VolitionRX in a report on Tuesday, June 2nd. Finally, D. Boral Capital restated a “hold” rating on shares of VolitionRX in a report on Monday, April 20th. One analyst has rated the stock with a Buy rating and four have issued a Hold rating to the company. According to MarketBeat, VolitionRX currently has a consensus rating of “Hold” and a consensus target price of $40.00.

VolitionRX Stock Performance

The company has a 50 day moving average price of $2.76 and a 200 day moving average price of $4.25. The firm has a market cap of $12.00 million, a price-to-earnings ratio of -0.33 and a beta of 1.04.

VolitionRX (NYSEAMERICAN:VNRX) last announced its quarterly earnings results on Thursday, May 14th. The medical research company reported ($0.97) EPS for the quarter, missing the consensus estimate of ($0.70) by ($0.27). The firm had revenue of $0.99 million during the quarter, compared to analyst estimates of $1.52 million. On average, research analysts forecast that VolitionRX Limited will post -2.4 earnings per share for the current year.

Hedge Funds Weigh In On VolitionRX

Several large investors have recently modified their holdings of the business. Lagoda Investment Management L.P. lifted its stake in shares of VolitionRX by 6.7% in the 3rd quarter. Lagoda Investment Management L.P. now owns 12,487,000 shares of the medical research company’s stock valued at $8,476,000 after purchasing an additional 782,000 shares during the last quarter. Armistice Capital LLC lifted its stake in VolitionRX by 10.4% during the 3rd quarter. Armistice Capital LLC now owns 9,380,425 shares of the medical research company’s stock worth $6,367,000 after acquiring an additional 887,351 shares in the last quarter. Geode Capital Management LLC lifted its stake in VolitionRX by 9.8% during the 4th quarter. Geode Capital Management LLC now owns 963,986 shares of the medical research company’s stock worth $246,000 after acquiring an additional 85,816 shares in the last quarter. Citadel Advisors LLC lifted its stake in VolitionRX by 70.1% during the 3rd quarter. Citadel Advisors LLC now owns 329,520 shares of the medical research company’s stock worth $224,000 after acquiring an additional 135,775 shares in the last quarter. Finally, Squarepoint Ops LLC acquired a new position in VolitionRX during the 4th quarter worth about $34,000. Institutional investors and hedge funds own 8.09% of the company’s stock.

VolitionRX Company Profile

VolitionRX, traded as VNRX on the NYSE American exchange, is a pioneering life sciences company focused on the development and commercialization of minimally invasive diagnostic tests for the early detection of cancer and other diseases. Utilizing proprietary technology to analyze circulating nucleosomes in blood samples, the company’s platform identifies disease-specific epigenetic and biochemical signatures. By offering blood-based screening solutions, VolitionRX aims to deliver alternatives to invasive, costly and time-consuming procedures, potentially improving patient outcomes through earlier diagnosis.

The company’s flagship product suite, branded as Nu.Q, comprises assays designed to detect biomarkers associated with a range of malignancies, including colorectal, lung and pancreatic cancers, as well as other systemic conditions.